Gan & Lee's obesity drug goes global as pipeline and profits advance
Menarini deal takes obesity drug to Europe Gan & Lee licensed its biweekly obesity drug bofanglutide to Menarini for 39 European countries. It gets 62 million euros upfront, up to 664 million euros in milestones, and royalties — total potential value 726 million euros. This is its fourth and largest overseas deal, proving the drug's global value and boosting future revenue.
This is the biggest new event, directly adding cash and validating the company's key pipeline.
Oral weekly diabetes drug moves to human trials Gan & Lee's GZC8072 tablets won Chinese clinical trial approval for type 2 diabetes. It is an oral peptide taken once a week, a next-generation product from its own technology platforms. This opens a large, convenient oral market and strengthens its long-term pipeline beyond injectables.
New regulatory milestone for a key pipeline asset, showing future growth potential.
Ethiopian approval opens new insulin market Ethiopia approved Gan & Lee's insulin aspart injection Rapilin for diabetes. Ethiopia has about 2.3 million diabetes patients and no other insulin aspart products, so this is a first-mover opportunity. It follows EU and Bolivia approvals, expanding the company's international reach.
New market approval that adds to the company's growing international revenue stream.
First-half profit and cash flow stay solid Gan & Lee reported first-half 2026 revenue of 2.223 billion yuan and net profit of 610 million yuan, with strong cash inflow and a very low debt ratio. International revenue jumped 92% year on year, showing its overseas push is paying off and supporting the stock's valuation.
Confirms the company's financial health and growth, underpinning investor confidence.